Opportunity Information: Apply for RFA HL 18 008
Catalyzing Innovation in Late Phase Clinical Trial Design and Statistical Analysis Plans (U34) is a National Institutes of Health funding opportunity from the National Heart, Lung, and Blood Institute (NHLBI) designed to support the planning stage of investigator-initiated clinical trials in phase II and later. The central goal is to help research teams turn important NHLBI-relevant clinical questions into feasible, well-justified, and operationally sound trial proposals, especially when the trials require non-traditional designs that create room for statistical novelty or methodological innovation. Rather than paying primarily for running a full clinical trial, this mechanism focuses on the preparatory work needed to produce a high-quality late-phase trial design and a rigorous statistical analysis plan that can stand up to scientific, regulatory, and real-world implementation demands.
A distinguishing feature of this opportunity is its emphasis on innovative trial design approaches. Applicants are expected to be working on late-stage clinical trials that do not fit neatly into conventional randomized controlled trial templates and that benefit from advanced design or analysis strategies. In practice, this can include designs such as adaptive trials, pragmatic trials embedded in health systems, cluster-randomized approaches, platform or master protocol concepts, enrichment strategies, Bayesian or other novel inferential frameworks, or other non-traditional methods aimed at improving efficiency, ethical conduct, interpretability, or generalizability. The FOA is positioned for projects where statistical thinking is not an afterthought, but a central driver of trial credibility and impact.
The award is a cooperative agreement (U34), which signals that NHLBI expects an active partnership role rather than a purely hands-off grant. A key part of that partnership is the use of consultative services from the Innovative Clinical Trials Resource (ICTR) under an N01 contract. The intent is to pair awardees with specialized expertise to refine and strengthen the trial plan, including design decisions, operational feasibility, endpoint selection, data collection strategy, randomization and masking procedures where applicable, and the statistical analysis plan. This consultative structure is meant to reduce avoidable design flaws and improve the likelihood that the eventual full-scale trial proposal will be both innovative and realistic to execute across single-site or multi-site settings.
The planning activities supported under this FOA generally align with what is needed to move from a promising clinical question to a trial that is ready for launch or ready for a subsequent, larger funding application. That includes developing a complete protocol framework, specifying primary and secondary endpoints, finalizing sample size and power or precision justifications suited to the chosen design, laying out interim monitoring rules if relevant (for example in adaptive settings), and producing a detailed statistical analysis plan that anticipates real-world complications such as missing data, non-adherence, site heterogeneity, multiplicity, subgroup analyses, and sensitivity analyses. Because the FOA highlights feasibility and good design, it implicitly favors planning packages that show a clear path to implementation, including recruitment and retention strategies, site readiness considerations, and practical data management approaches.
Eligibility is broad and includes many types of U.S.-based organizations and governmental entities. Eligible applicants listed include state, county, and city or township governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; public housing authorities and Indian housing authorities; and a range of nonprofit organizations (both with and without 501(c)(3) status) outside of higher education. For-profit organizations (other than small businesses) and small businesses are also eligible, as are certain other categories. The FOA explicitly calls out additional eligible applicant types such as Alaska Native and Native Hawaiian Serving Institutions; Asian American, Native American, and Pacific Islander Serving Institutions (AANAPISIs); Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Tribally Controlled Colleges and Universities (TCCUs); eligible federal agencies; faith-based or community-based organizations; regional organizations; Indian/Native American tribal governments other than federally recognized; and U.S. territories or possessions.
The foreign eligibility rules are nuanced. Non-domestic (non-U.S.) entities and foreign institutions are not eligible to apply as the primary applicant organization. However, non-domestic components of U.S. organizations are eligible, and foreign components (as NIH defines them in the NIH Grants Policy Statement) are allowed. In practical terms, that means a U.S. applicant can include foreign sites or collaborations when they are well justified and appropriately structured, but an organization based outside the U.S. cannot be the applicant institution for this U34.
From an administrative standpoint, this opportunity is categorized as discretionary funding and uses the health funding activity category. The opportunity number is RFA HL 18 008, and the funding opportunity title is as listed above. CFDA numbers associated with it include 93.233 and 93.837 through 93.840. The original closing date provided is January 12, 2018, and the creation date is May 17, 2017. The award ceiling listed is $125,000, which reinforces the planning-focused nature of the mechanism rather than full trial execution. The expected number of awards is not specified in the provided data.
Overall, the FOA is best understood as a targeted planning grant for teams preparing late-phase NHLBI-aligned clinical trials where the design and analysis require creativity and sophistication. It aims to reduce the gap between a compelling clinical question and a fundable, executable protocol by supporting intensive design and analysis planning, strengthened through consultation with NHLBI-supported clinical trials methodology resources.Apply for RFA HL 18 008
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Catalyzing Innovation in Late Phase Clinical Trial Design and Statistical Analysis Plans (U34)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.233, 93.837, 93.838, 93.839, 93.840.
- This funding opportunity was created on 2017-05-17.
- Applicants must submit their applications by 2018-01-12. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $125,000.00 in funding.
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQs)
What is the purpose of the Catalyzing Innovation in Late Phase Clinical Trial Design and Statistical Analysis Plans (U34) opportunity?
This National Institutes of Health (NIH) funding opportunity from the National Heart, Lung, and Blood Institute (NHLBI) supports the planning stage for investigator-initiated clinical trials in phase II and later. Its main purpose is to help research teams convert important NHLBI-relevant clinical questions into feasible, well-justified, and operationally sound late-phase trial proposals, particularly when non-traditional designs and advanced statistical approaches are needed.
Is this funding meant to pay for running the full clinical trial?
No. This U34 mechanism is focused on preparatory and planning activities, not primarily on conducting a full-scale clinical trial. The emphasis is on producing a strong late-phase trial design and a rigorous statistical analysis plan that can meet scientific, regulatory, and real-world implementation expectations.
What trial phases are targeted by this opportunity?
The opportunity is designed for planning investigator-initiated clinical trials in phase II and later (late-phase trials).
What makes this FOA different from more conventional clinical trial planning support?
A distinguishing feature is its emphasis on innovative, non-traditional trial designs and statistical approaches. It is positioned for projects where statistical and methodological considerations are central to the trial concept, rather than added later as an afterthought.
What kinds of trial designs are considered "non-traditional" or innovative under this opportunity?
Examples listed or implied include adaptive trials, pragmatic trials embedded in health systems, cluster-randomized designs, platform trials or master protocol approaches, enrichment strategies, Bayesian or other novel inferential frameworks, and other non-traditional methods intended to improve efficiency, ethical conduct, interpretability, or generalizability.
What is a U34 award in this context?
The award is a cooperative agreement (U34). This indicates that NHLBI expects to play an active partnership role rather than providing purely hands-off support.
What does "cooperative agreement" mean for how the project is supported?
Under a cooperative agreement, NHLBI anticipates active involvement, including structured consultation and partnership elements. A key feature described is the use of consultative services to refine and strengthen the trial plan.
What is the Innovative Clinical Trials Resource (ICTR), and how does it relate to this award?
The opportunity includes consultative services from the Innovative Clinical Trials Resource (ICTR) under an N01 contract. The intent is to pair awardees with specialized expertise to strengthen the design and planning package for a late-phase trial.
What kinds of topics can the ICTR consultation help refine?
The consultation is intended to support improvements across core planning elements such as trial design decisions, operational feasibility, endpoint selection, data collection strategy, randomization and masking procedures (when applicable), and the statistical analysis plan.
What kinds of planning activities are supported by this FOA?
Supported activities generally align with what is needed to move from a promising clinical question to a trial that is ready for launch or ready for a subsequent, larger funding application. This includes developing a protocol framework, defining primary and secondary endpoints, finalizing sample size and power (or precision) justifications appropriate to the design, planning interim monitoring rules when relevant (including for adaptive designs), and producing a detailed statistical analysis plan.
What statistical analysis plan elements does the FOA highlight as important to anticipate?
The FOA emphasizes the need for a rigorous statistical analysis plan that anticipates real-world complications, including missing data, non-adherence, site heterogeneity, multiplicity, subgroup analyses, and sensitivity analyses.
Does this opportunity emphasize feasibility and real-world implementation planning?
Yes. The FOA highlights feasibility and good design and implicitly favors planning packages that demonstrate a clear path to implementation. Examples mentioned include recruitment and retention strategies, site readiness considerations, and practical data management approaches.
Who is eligible to apply?
Eligibility is broad and includes many U.S.-based organizations and governmental entities. Eligible applicants listed include state, county, city or township governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; public housing authorities and Indian housing authorities; and nonprofit organizations (with or without 501(c)(3) status) outside of higher education. For-profit organizations (other than small businesses) and small businesses are also eligible, along with additional specified categories.
Are minority-serving institutions and tribally controlled institutions included in the eligible applicant types?
Yes. The FOA explicitly calls out eligible applicant types that include Alaska Native and Native Hawaiian Serving Institutions; Asian American, Native American, and Pacific Islander Serving Institutions (AANAPISIs); Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); and Tribally Controlled Colleges and Universities (TCCUs).
Are faith-based, community-based, or regional organizations eligible to apply?
Yes. The eligible applicant types explicitly include faith-based or community-based organizations and regional organizations.
Can federal agencies apply?
Yes. Eligible applicant types include eligible federal agencies.
Are U.S. territories or possessions included in the eligibility list?
Yes. The FOA lists U.S. territories or possessions among the eligible applicant types.
Can a non-U.S. (foreign) organization apply as the primary applicant?
No. Non-domestic (non-U.S.) entities and foreign institutions are not eligible to apply as the primary applicant organization for this U34.
Can a U.S. applicant include foreign sites or collaborations?
Yes. The foreign eligibility rules described are nuanced: non-domestic components of U.S. organizations are eligible, and foreign components (as NIH defines them in the NIH Grants Policy Statement) are allowed. In practice, a U.S. applicant may include foreign sites or collaborations when well justified and appropriately structured.
What is the opportunity number for this FOA?
The opportunity number is RFA HL 18 008.
Which NIH Institute is sponsoring this opportunity?
This opportunity is from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH).
What is the funding type and activity category?
The opportunity is categorized as discretionary funding and uses the health funding activity category.
What CFDA numbers are associated with this opportunity?
The CFDA numbers listed include 93.233 and 93.837 through 93.840.
What is the maximum award amount (ceiling) listed?
The award ceiling listed is $125,000, consistent with a planning-focused mechanism rather than full trial execution.
How many awards are expected?
The expected number of awards is not specified in the provided information.
What were the dates provided for this opportunity?
The creation date provided is May 17, 2017. The original closing date provided is January 12, 2018.
What is the overall goal of this planning grant in plain terms?
The overall goal is to reduce the gap between a compelling NHLBI-aligned clinical question and a fundable, executable late-phase trial protocol by supporting intensive design and statistical analysis planning, strengthened through consultation with NHLBI-supported clinical trials methodology resources.
Browse more opportunities from the same category: Health
Next opportunity: FY2018 VANNEVAR BUSH FACULTY FELLOWSHIP
Previous opportunity: Uncovering the Causes, Contexts, and Consequences of Elder Mistreatment (R01)
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA HL 18 008
Applicants also applied for:
Applicants who have applied for this opportunity (RFA HL 18 008) also looked into and applied for these:
| Funding Opportunity |
|---|
| Behavioral Interventions for Prevention of Opioid Use Disorder or Adjunct to Medication Assisted Treatment-SAMHSA Opioid STR Grants (R21/R33) Apply for RFA AT 18 001 Funding Number: RFA AT 18 001 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Exploratory Clinical Trial Grants in Arthritis and Musculoskeletal and Skin Diseases (R21) Apply for PAR 17 293 Funding Number: PAR 17 293 Agency: National Institutes of Health Category: Health Funding Amount: $400,000 |
| Catalyzing Innovation in Late Phase Clinical Trial Design and Statistical Analysis Plans (X01) Apply for RFA HL 18 009 Funding Number: RFA HL 18 009 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| HIV Drug Resistance: Genotype-Phenotype-Outcome Correlations (R01) Apply for PA 17 291 Funding Number: PA 17 291 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| HIV Drug Resistance: Genotype-Phenotype-Outcome Correlations (R21) Apply for PA 17 292 Funding Number: PA 17 292 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Catalyzing Innovation in Late Phase Clinical Trial Design and Statistical Analysis Plans Resource Access (X01) Apply for PAR 17 294 Funding Number: PAR 17 294 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Stakeholder Consultative Workshop in Guatemala Apply for NEWHEALTHACTIVITY Funding Number: NEWHEALTHACTIVITY Agency: Guatemala USAID-Guatemala City Category: Health Funding Amount: Case Dependent |
| Alcohol-Induced Effects on Tissue Injury and Repair (R01) Apply for PA 17 297 Funding Number: PA 17 297 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| AHRQ National Research Service Award (NRSA) Institutional Research Training Grant (T32) Apply for RFA HS 17 011 Funding Number: RFA HS 17 011 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: Case Dependent |
| Alcohol-Induced Effects on Tissue Injury and Repair (R21) Apply for PA 17 296 Funding Number: PA 17 296 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Grants for Early Medical/Surgical Specialists' Transition to Aging Research (GEMSSTAR) (R03) Apply for RFA AG 18 015 Funding Number: RFA AG 18 015 Agency: National Institutes of Health Category: Health Funding Amount: $75,000 |
| Socioeconomic Disparities in Health and Mortality at Older Ages (R01) Apply for RFA AG 18 011 Funding Number: RFA AG 18 011 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Partnerships for the Development of Vaccines and Immunophrophylactics Targeting Multiple Antimicrobial-Resistant Bacteria (R01) Apply for RFA AI 17 017 Funding Number: RFA AI 17 017 Agency: National Institutes of Health Category: Health Funding Amount: $750,000 |
| Partnerships for Development of Clinically Useful Diagnostics for Antimicrobial-Resistant Bacteria (R01) Apply for RFA AI 17 014 Funding Number: RFA AI 17 014 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Limited Competition: Small Grant Program for ORIP Special Emphasis Research Career Award (SERCA) K01 Recipients (R03) Apply for PAR 17 301 Funding Number: PAR 17 301 Agency: National Institutes of Health Category: Health Funding Amount: $75,000 |
| NeuroNEXT Small Business Innovation in Clinical Trials (U44) Apply for PAR 17 300 Funding Number: PAR 17 300 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Optimizing HIV Phylodynamics to Target and Interrogate Clusters (OPTICs) (R21) Apply for PA 17 306 Funding Number: PA 17 306 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Institutional Development Award (IDeA) Program Infrastructure for Clinical and Translational Research (IDeA-CTR)(U54) Apply for PAR 17 304 Funding Number: PAR 17 304 Agency: National Institutes of Health Category: Health Funding Amount: $4,000,000 |
| Grants to Support the Historically Black Colleges and Universities Health Services Research Grant Program Apply for CMS 1I0 17 001 Funding Number: CMS 1I0 17 001 Agency: Centers for Medicare Medicaid Services Category: Health Funding Amount: $325,000 |
| Grants to Support the Hispanic Health Services Research Grant Program Apply for CMS 1H0 17 001 Funding Number: CMS 1H0 17 001 Agency: Centers for Medicare Medicaid Services Category: Health Funding Amount: $325,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA HL 18 008", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.